Nanomedicines with high drug availability and drug sensitivity overcome hypoxia-associated drug resistance.

Humans Cisplatin / pharmacology Prodrugs / pharmacology Nanomedicine Neoplasms / pathology Hypoxia / drug therapy Drug Resistance Cell Line, Tumor Hyaluronic Acid / pharmacology Nanoparticles / therapeutic use Tumor Microenvironment
Cisplatin resistance Drug delivery Hypoxia-responsive nanoparticle Nucleotide excision repair Tumor hypoxia heterogeneity

Journal

Biomaterials
ISSN: 1878-5905
Titre abrégé: Biomaterials
Pays: Netherlands
ID NLM: 8100316

Informations de publication

Date de publication:
03 2023
Historique:
received: 23 08 2022
revised: 17 12 2022
accepted: 20 01 2023
pubmed: 29 1 2023
medline: 16 2 2023
entrez: 28 1 2023
Statut: ppublish

Résumé

Tumor hypoxia heterogeneity, a hallmark of the tumor microenvironment, confers resistance to conventional chemotherapy due to insufficient drug availability and drug sensitivity in hypoxic regions. To overcome these challenges, we develope a nanomedicine, NP

Identifiants

DOI: 10.1016/j.biomaterials.2023.122023 PMID: 36708621
pubmed: 36708621
pii: S0142-9612(23)00031-5
doi: 10.1016/j.biomaterials.2023.122023
pii:
doi:

Substances chimiques

azobenzene F0U1H6UG5C
Cisplatin Q20Q21Q62J
Prodrugs 0
Hyaluronic Acid 9004-61-9

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

122023

Informations de copyright

Copyright © 2023 Elsevier Ltd. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

Yi Liu (Y)

Department of Radiology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, 230001, China; The CAS Key Laboratory of Innate Immunity and Chronic Disease, School of Basic Medical Sciences, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, 230027, China.

Wang Dong (W)

The CAS Key Laboratory of Innate Immunity and Chronic Disease, School of Basic Medical Sciences, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, 230027, China.

Yinchu Ma (Y)

The CAS Key Laboratory of Innate Immunity and Chronic Disease, School of Basic Medical Sciences, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, 230027, China.

Jiaxiang Dou (J)

The CAS Key Laboratory of Innate Immunity and Chronic Disease, School of Basic Medical Sciences, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, 230027, China.

Wei Jiang (W)

The CAS Key Laboratory of Innate Immunity and Chronic Disease, School of Basic Medical Sciences, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, 230027, China.

Li Wang (L)

The CAS Key Laboratory of Innate Immunity and Chronic Disease, School of Basic Medical Sciences, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, 230027, China.

Qin Wang (Q)

The CAS Key Laboratory of Innate Immunity and Chronic Disease, School of Basic Medical Sciences, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, 230027, China.

Shuya Li (S)

The CAS Key Laboratory of Innate Immunity and Chronic Disease, School of Basic Medical Sciences, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, 230027, China.

Yucai Wang (Y)

Department of Radiology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, 230001, China; The CAS Key Laboratory of Innate Immunity and Chronic Disease, School of Basic Medical Sciences, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, 230027, China; Institute of Health and Medicine, Hefei Comprehensive National Science Center, Hefei, Anhui, 230601, China. Electronic address: yucaiwang@ustc.edu.cn.

Min Li (M)

Department of Radiology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, 230001, China; The CAS Key Laboratory of Innate Immunity and Chronic Disease, School of Basic Medical Sciences, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, 230027, China. Electronic address: limin09@ustc.edu.cn.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Nanomedicines with high drug availability and...
questionsmedicales.fr › Produits chimiques inorganiques › Composés du platine › Cisplatine › Nanomedicines with high drug availability and...
questionsmedicales.fr › Préparations pharmaceutiques › Promédicaments › Nanomedicines with high drug availability and...
questionsmedicales.fr › Technologie, industrie et agriculture › Technologie › Miniaturisation › Nanotechnologie › Nanomédecine › Nanomedicines with high drug availability and...
questionsmedicales.fr › Tumeurs › Nanomedicines with high drug availability and...
questionsmedicales.fr › États, signes et symptômes pathologiques › Signes et symptômes › Signes et symptômes respiratoires › Hypoxie › Nanomedicines with high drug availability and...
questionsmedicales.fr › Phénomènes physiologiques › Phénomènes pharmacologiques et toxicologiques › Phénomènes pharmacologiques › Résistance aux substances › Nanomedicines with high drug availability and...
questionsmedicales.fr › Cellules › Cellules cultivées › Cellules cancéreuses en culture › Lignée cellulaire tumorale › Nanomedicines with high drug availability and...
questionsmedicales.fr › Glucides › Polyosides › Glycosaminoglycanes › Acide hyaluronique › Nanomedicines with high drug availability and...
questionsmedicales.fr › Technologie, industrie et agriculture › Produits manufacturés › Nanostructures › Nanoparticules › Nanomedicines with high drug availability and...
questionsmedicales.fr › Phénomènes physiologiques cellulaires › Microenvironnement cellulaire › Microenvironnement tumoral › Nanomedicines with high drug availability and...